Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis
Journal of Clinical Pharmacy and Therapeutics · 2022-02 · 47 (2) · 146-156
DOI: 10.1111/jcpt.13481 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 28.07.2021. Verfasst von Qinhua Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: GlaxoSmithKline (China) R&D Company Limited.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- GlaxoSmithKline, Beijing, China.
- GlaxoSmithKline, Collegeville, PA, USA.
- Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Zhuang Tian
Förderung
- GlaxoSmithKline (China) R&D Company Limited
Zitieren
APA
Zhao, Q., Guo, N., Chen, J., Parks, D., & Tian, Z. (2022). Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics, 47(2), 146-156. https://doi.org/10.1111/jcpt.13481
Vancouver
Zhao Q, Guo N, Chen J, Parks D, Tian Z. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics. 2022;47(2):146-156. doi:10.1111/jcpt.13481
BibTeX
@article{Zhao2022,
author = {Zhao, Qinhua and Guo, Na and Chen, Jun and Parks, Daniel and Tian, Zhuang},
title = {Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2022},
volume = {47},
number = {2},
pages = {146--156},
doi = {10.1111/jcpt.13481}
}
EUVIMED